Theragen Etex

Theragen Etex is a prominent South Korean healthcare company that bridges the gap between traditional pharmaceutical manufacturing and cutting-edge genomic science. The company operates through its pharmaceutical division, which produces a wide range of prescription and over-the-counter drugs, and its specialized genomics subsidiary, Theragen Bio, which focuses on next-generation sequencing (NGS) and personalized medicine. Theragen Etex is recognized for being the first in Korea to map the human genome and continues to lead in the development of genomic-based diagnostic services like HelloGene and Mediscan. Their research pipeline includes innovative neoantigen-based cancer vaccines and targeted therapies developed through big data analysis. The company is publicly traded on the KOSDAQ and maintains a strong presence in both the domestic and international biotechnology markets.